Patents Represented by Attorney Marc A. Began, Esq.
-
Patent number: 6669090Abstract: The invention relates to: A method of providing an electronically readable item of information (725) on a medication cartridge (70). The invention further relates to a cartridge (70) containing an electronically readable item of information (725), a support (75) for reading the information (725) on the cartridge (70), a medication delivery device adapted to use a cartridge (70) and a support (75) according to the invention and a label (72) containing an electronically readable item of information (725). The object of the present invention is to provide an alternative method of generating an electronically readable item of information on a cartridge which method is simple and improves safety in reading. The problem is solved in that said item of information is redundantly provided (725, 726). The invention may e.g. be used in connection with medication delivery devices for self-treatment of a disease, e.g. diabetes.Type: GrantFiled: August 9, 2001Date of Patent: December 30, 2003Assignee: Novo Nordick A/SInventor: Michael Eilersen
-
Patent number: 6663602Abstract: An injection device for injection of set does of medicine from a cartridge has a nut that is screwed up along a threaded piston rod during a dose setting operation. The nut is screwed along the piston rod by rotating a dose setting drum. An injection button is coupled to the piston rod with a gear wheel transmission. Axial movement of the injection button causes a corresponding axial movement of the piston rod until the nut engages an abutment in the housing.Type: GrantFiled: June 14, 2001Date of Patent: December 16, 2003Assignee: Novo Nordisk A/SInventor: Claus Schmidt Møller
-
Patent number: 6660197Abstract: The present invention relates to a method and a system for producing an elongated drug formulation being suitable for being injected through the skin of a patient with-out the use of a needle or a cannula. The drug formulation is produced by compressing a drug granulate in cavity of a system comprising a roller and a surface, wherein the roller roles over the surface thereby comprising the granulate to the formulation.Type: GrantFiled: October 12, 2000Date of Patent: December 9, 2003Assignee: Novo Nordisk A/SInventors: Thomas Buch-Rasmussen, Søren Aasmul, James M. Flink, Philip Hansen, Claus Juul-Mortensen, Jens-Ulrik Poulsen
-
Patent number: 6656114Abstract: A method of self treating a disease, such as diabetes, includes collecting in one or more databases data representing values of parameters that related to the self treatment. The data is processed to provide a plurality of alternate choices between two or more actions that may be taken and a corresponding value for each action is calculated. A computerized system may be employed to perform the above method and the system may include a computer readable medium for executing the method.Type: GrantFiled: October 30, 2000Date of Patent: December 2, 2003Assignee: Novo Noadisk A/SInventors: Jens Ulrik Poulsen, Lars Hofmann Christensen, Søren Aasmul
-
Patent number: 6653492Abstract: Certain bile acids find use in the pharmaceutical industry. In view of the wide distribution of serious diseases such as HIV, AIDS and Bovine Spongiform Encephalopathy (BSE) it is desirable to avoid—as far as practicable—to have any components of animal origin in medicaments in order to eliminate any danger of infection. The present invention relates to a method of providing bile acids from non-animal starting materials.Type: GrantFiled: May 1, 2002Date of Patent: November 25, 2003Assignee: Novo Nordick A/SInventor: Peter Faarup
-
Patent number: 6649641Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.Type: GrantFiled: November 16, 2001Date of Patent: November 18, 2003Assignee: Novo Nordisk A/SInventors: Carsten Behrens, Jesper Lau, Peter Madsen
-
Patent number: 6645953Abstract: Sterol derivative compounds, structurally related to natural compounds which can be extracted from bull testes and from human follicular fluid, useful for regulating meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives.Type: GrantFiled: June 11, 2001Date of Patent: November 11, 2003Assignee: Novo Nordisk A/SInventors: Frederik Christian Gronvald, Peter Faarup, Erling Guddal
-
Patent number: 6639515Abstract: A method for clinical surveillance of a treatment group and an other group involves defining an adverse event, possible a serious adverse event, noting each occurrence of the adverse events, and, starting at zero, calculating a cumulative sum of the adverse events by updating the cumulative sum each time a further adverse event is reported and, when the adverse event is in the treatment group, adding 1 to the cumulative sum, and, when the adverse event is in the other group, adding 0 to the cumulative sum. This invention also involves subtracting a chosen quantity K from the cumulative sum, comparing the cumulative sum to a predetermined alarm limit, determining when the cumulative sum reaches at least the predetermined alarm limit, and indicating the predetermined alarm limit has been reached.Type: GrantFiled: October 11, 2001Date of Patent: October 28, 2003Assignee: Novo Nordisk A/SInventor: Philip Hougaard
-
Patent number: 6620780Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: GrantFiled: May 21, 2001Date of Patent: September 16, 2003Assignee: Novo Nordisk A/SInventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Patent number: 6620112Abstract: A disposable lancet combined with a reagent carrying strip which carries a reagent that indicates the concentration of a blood component in a blood sample placed in contact with the strip. The reagent carrying strip is connected to the lancet, e.g. by molding. One end of the lancet is sharpened for piercing the skin. The strip is sheet-like and has a first side and a second side, which sides are both accessible for the user, such that the reagent carrying strip can be inserted into a blood glucose meter. A weakened tear line is provided at a connection between the lancet and an edge of the reagent carrying strip so that the reagent carrying strip may be easily disconnected from the lancet.Type: GrantFiled: March 14, 2001Date of Patent: September 16, 2003Assignee: Novo Nordisk A/SInventor: Lars Peter Klitmose
-
Patent number: 6613942Abstract: Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.Type: GrantFiled: December 23, 1998Date of Patent: September 2, 2003Assignee: Novo Nordisk A/SInventors: Anthony Ling, Vlad Gregor, Javier Gonzalez, Yufeng Hong, Dan Kiel, Atsuo Kuki, Shenghua Shi, Lars Naerum, Peter Madsen, Christian Sams, Jesper Lau, Michael Bruno Plewe, Jun Feng, Min Teng, Michael David Johnson, Kimberly Ann Teston, Ulla Grove Sidelmann, Lotte Bjerre Knudsen
-
Patent number: 6613019Abstract: A liquid medication delivery device for, and a method of, delivering medication from a cartridge having a moveable piston at one end is disclosed. The piston has a first wall face that contacts the liquid in the cartridge and a second wall for engaging a piston rod that drives the piston. The first and second walls are moveable but the second wall tends to move more quickly then the first during administration of a dose of medication from the cartridge. To compensate for this difference in movement between the first and second wall faces, the rod first moves a distance corresponding to the amount that the first wall face must move to deliver the desired dose and then it continues to move past this position by an amount known as an overshoot distance. It is then retracted by a distance equal to the overshoot distance.Type: GrantFiled: July 13, 2001Date of Patent: September 2, 2003Assignee: Novo Nordisk A/SInventor: Jens Aage Munk
-
Patent number: 6590072Abstract: The present invention relates to a method for extractive refolding of scrambled and/or polymerised single-chain polypeptides or proteins into their native conformation directly from a microbial fermentation broth.Type: GrantFiled: January 23, 2001Date of Patent: July 8, 2003Assignee: NNA/SInventor: Ivan Diers
-
Patent number: 6586574Abstract: The invention relates to the use of glycylglycine, optionally in combination with a sugar, and/or a sugar alcohol, and/or an amino acid, as a bulking agent in freeze-drying.Type: GrantFiled: August 15, 2000Date of Patent: July 1, 2003Assignee: NN A/SInventor: Lars Lindgaard Hansen
-
Patent number: 6585699Abstract: A drug delivery device comprising a housing (1) with a drug container (2) being provided with delivering means comprising a piston (5) for expelling a drug (4) from the drug container (2). The housing (1) further comprising a displaceable piston rod (6) abutting the piston (5) of the drug container (2) and rotating means being in engagement with the piston rod (6), said rotating means being provided with a one-way mechanism. The one-way mechanism comprises a helical spring (12) wound tightly around an axle (11), one end of said helical spring (12) being fixed in relation to the housing (1), the other end of the helical spring (12) being in a free state.Type: GrantFiled: March 30, 2001Date of Patent: July 1, 2003Assignee: NNA/SInventors: Henrik Ljunggreen, Jens Ulrik Poulsen, Soren Aasmul, Lars Hofmann Christensen, Jens Moller-Jensen, Peter Moller-Jensen
-
Patent number: 6582408Abstract: The present invention relates to a medication delivery device comprising a cartridge assembly, a dosing assembly and optionally a needle assembly. The cartridge assembly comprises a cartridge having a stopper adapted to receive a plunger. Furthermore, the cartridge assembly has one end sealed with a pierce able sealing, said end comprising coupling device for engaging a needle assembly, and another end comprising coupling device for engaging the dosing assembly. The dosing assembly comprises a plunger and has coupling device for engaging the cartridge assembly. The cartridge assembly and the dosing assembly are coupled together for delivering selected doses of medication. The device further comprises mechanism for securing that the plunger abuts on the stopper during use of the device, in particular when the dosing assembly is releasable coupled to the cartridge assembly.Type: GrantFiled: July 8, 1999Date of Patent: June 24, 2003Inventors: Thomas Buch-Rasmussen, Benny Munk, Jens Ulrik Poulsen, Henrik Ljungreen, Peter Møller Jensen, Jens Møller Jensen
-
Patent number: 6582404Abstract: A limiting mechanism which prevents the setting of a dose, which exceeds the amount of liquid left in a cartridge of an injection device, is disclosed. The injection device is the type where a dose is set by rotating a dose setting member relative to a driver and away from a fixed stop in the injection device. The dose setting member interfaces the driver such that the dose setting member can be rotated in one direction without rotating the driver. The dose is injected by rotating back the dose setting member which during the backward rotation carries the driver with it. Rotating the driver causes the piston rod to move forward inside the cartridge and expel some of the liquid contained in the cartridge. The driver is provided with a track having a length which is related to the total amount of liquid in the cartridge and which track is engaged by a track follower coupled to the dose setting member to follow rotation of this dose setting member.Type: GrantFiled: September 6, 2000Date of Patent: June 24, 2003Assignee: NNA/SInventors: Peter Christian Klitgaard, Steffen Hansen, Bo Radmer, Claus Schmidt Møller
-
Patent number: 6569832Abstract: This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.Type: GrantFiled: November 10, 2000Date of Patent: May 27, 2003Assignee: Novo Nordisk A/SInventors: Liselotte Bjerre Knudsen, Carsten Foged Godtfredsen, Jacob Sten Petersen, Richard David Carr, Søren Bregenholt
-
Patent number: 6569126Abstract: By a cylinder ampoule (1), comprising a tubular vessel with a membrane (4) sealingly closing one end and a piston (9) closing the other end, liquid stored between said piston (9) and said membrane (4) can be pressed out through an injection needle (7) piercing the membrane (4) when the piston (9) is pressed into the ampoule (1). The tube is made from a plastically deformable material. A pressure foot (10) on which a piston rod (13) is acting abuts the piston (9), carries a spring plate (11) made from a harder material than is the ampoule (1), is mainly perpendicular to the ampoule (1) axis, and has at least one diameter which is larger than the inner diameter of the ampoule (1) so that edges of the plate (11) abutting the inner wall of the ampoule (1) are deflected away from the piston (9) to form an acute angle with said wall.Type: GrantFiled: July 8, 1998Date of Patent: May 27, 2003Assignee: Novo Nordisk A/SInventors: Jens Ulrik Poulsen, Jens Møller-Jensen
-
Patent number: 6566329Abstract: A readily-soluble freeze-dried solid preparation of hGH with a minimal content of degradation products in terms of deamidation, dimers, polymers, and sulphoxide forms, obtainable by a method comprising a single lyophilization of an aqueous slurry of an amorphous hGH isoprecipitate, the slurry having a pH of from about 4.7 to 5.0 and being essentially free of buffer components other than acetate.Type: GrantFiled: June 14, 2000Date of Patent: May 20, 2003Assignee: Novo Nordisk A/SInventors: Giorgio Meyn, Hans Holmegaard Sørensen, Thorkild Christensen